Figure 2.
In vitro VpreB1-ADC efficacy against B-ALL. VpreB1 antibody (A,C) and VpreB1-ADC (B,D) dose-response curves for leukemia cell lines (A-B) and B-ALL PDX models (C-D). Leukemia cell viability was assessed after 48 hours of treatment using the CellTiter-Glo Luminescent Cell Viability Assay. Error bars represent the mean ± SD of 3 technical replicates.

In vitro VpreB1-ADC efficacy against B-ALL. VpreB1 antibody (A,C) and VpreB1-ADC (B,D) dose-response curves for leukemia cell lines (A-B) and B-ALL PDX models (C-D). Leukemia cell viability was assessed after 48 hours of treatment using the CellTiter-Glo Luminescent Cell Viability Assay. Error bars represent the mean ± SD of 3 technical replicates.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal